It should come as no surprise that one of the top biotech stocks to consider right now, as identified by the author of today’s article, is a coronavirus play whose COVID-19 vaccine candidate has just been approved by the FDA for Phase II clinical trials: Moderna. For the author’s other two top picks from the “recession-proof” biotech sector – which he notes could grow to $775 billion by 2024 – CLICK HERE.